MedTrace Logo

BNP for Cardio-Renal Decompensation Syndrome (BNP-CARDS)

NCT00186329 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2015-04-28

No results posted yet for this study

Summary

Many patients with exacerbations of heart failure have significant concomitant kidney dysfunction. The combination of these two conditions makes pharmacological management difficult. In this study, we plan to randomize patients with heart failure and kidney dysfunction to receive infusions of Natrecor (B-type Natriuretic Peptide)--which may be beneficial to the management of these two diseases--or placebo.

Conditions

  • Congestive Heart Failure Exacerbation
  • Renal Insufficiency

Interventions

DRUG

Natrecor, a recombinant form of B-type Natriuretic Peptide, made by Scios, Inc. vs. placebo

Sponsors & Collaborators

Principal Investigators

  • Michael B Fowler, MB · Professor, School of Medicine, Stanford University

  • Ronald Witteles, MD · Cardiology Fellow, Stanford University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-03-31
Completion
2006-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00186329 on ClinicalTrials.gov